Data Suggests Improved Disease Control With FASLODEXTM 500mg Compared With Anastrozole For Women With Hormone Receptor-positive Breast Cancer

Links shared publicly online about this topic.

  • 665
    total visits

Data Suggests Improved Disease Control With FASLODEXTM 500mg Compared With Anastrozole For Women With Hormone Receptor-positive Breast Cancer

medicalnewstoday.com —

New data presented at the CTRC-AACR 33rd Annual San Antonio Breast Cancer Symposium, USA, suggest fulvestrant 500mg offers improved disease control compared with the aromatase inhibitor, anastrozo

View full resource at medicalnewstoday.com

Tags: Hormone, Cancer, Breast Cancer, Breast Cancer Medication, Disease and Condition, Women's Health, Arimidex, disease

  • Share

Most Recently Shared on December 11, 2010 at 12:05 am By:

mnt_cancer MNT Cancer News

Data Suggests Improved Disease Control With FASLODEXTM 500mg Compared With Anastrozole For Women With Hormone Receptor... http://mnt.to/3NSq

1 year ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Breast Cancer MNT Breast Cancer

Advertisement